AKYNZEO® (Netupitant/Palonosetron) is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, and prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy.*
ALOXI® (Palonosetron) is indicated in adults for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, and the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy. It may be used in paediatric patients aged 1 month to less than 17 years for the prevention of acute nausea and vomiting associated with moderately or highly emetogenic cancer chemotherapy. Aloxi is also indicated for prevention of post-operative nausea and vomiting for up to 24 hrs following surgery.*
ANAMORELIN is a novel once-daily, orally active ghrelin receptor agonist indicated for the treatment of cancer cachexia in patients suffering from malignant tumors of non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer or colorectal cancer. Cancer cachexia is a complex metabolic disorder syndrome, characterized by decreased body weight (especially decreased muscle mass) and anorexia associated with cancer. It has been well documented that cancer cachexia causes a significant impact on patients’ quality of life (QOL) and prognosis.*
CARIS MOLECULAR PROFILING
CARIS comprehensive molecular profiling approach precisely analyzes DNA, RNA, and protein biomarkers, revealing the highest quality molecular blueprint for evidence-based selection of the most appropriate cancer therapy. In addition to comprehensive molecular profiling, Caris has innovated industry-leading artificial intelligence algorithms that predict patient responses to standard treatments, such as immunotherapy or chemotherapy, based on their personalized molecular profile. Caris is the original, most experienced comprehensive molecular profiling laboratory, and we have optimized our systems to provide industry-leading reports, service and turnaround time. Caris molecular profiling helps oncologists:
*The exact therapeutic indication and registration status may be different in each country. Please consult the official approved product information in your country.